Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

Host-derived adiponectin is tumor-suppressive and a novel therapeutic target for multiple myeloma and the associated bone disease

Jessica A. Fowler, Seint T. Lwin, Matthew T. Drake, James R. Edwards, Robert A. Kyle, Gregory R. Mundy, Claire M. Edwards

Blood (2011) 118 (22): 5872–5882.

https://doi.org/10.1182/blood-2011-01-330407

Published: 2011

Includes: Supplemental data

Journal Articles

Bone Spared Myeloma.

Gregory R. Mundy, MD

Blood (2009) 114 (22): SCI-6.

https://doi.org/10.1182/blood.V114.22.SCI-6.SCI-6

Published: 2009

Journal Articles

Osteoclasts in Myeloma Are Derived from Gr-1 + CD11b + Myeloid Immune Suppressor Cells of the Bone Marrow Niche in Vivo

Junling Zhuang, M.D., Ph.D., Li Yang, Ph.D., Seint T Lwin, B.S., Claire M. Edwards, PhD, BSc, James R Edwards, Ph.D., Gregory R Mundy, M.D.

Blood (2008) 112 (11): 736.

https://doi.org/10.1182/blood.V112.11.736.736

Published: 2008

Journal Articles

Increasing Wnt signaling in the bone marrow microenvironment inhibits the development of myeloma bone disease and reduces tumor burden in bone in vivo

Claire M. Edwards, James R. Edwards, Seint T. Lwin, Javier Esparza, Babatunde O. Oyajobi, Brandon McCluskey, Steven Munoz, Barry Grubbs, Gregory R. Mundy

Blood (2008) 111 (5): 2833–2842.

https://doi.org/10.1182/blood-2007-03-077685

Published: 2008

Journal Articles

Protein Profiling in Myeloma In Vivo ; Effects of Bortezomib in a Mouse Model of Myeloma.

Claire M. Edwards, PhD, Robert L. Caldwell, PhD, Andreia L. Bates, Jessica A. Fowler, James R. Edwards, PhD, Babatunde O. Oyajobi, MD, PhD, Seint T. Lwin, Jianghong Zhang, PhD, Gregory R. Mundy, MD

Blood (2007) 110 (11): 255.

https://doi.org/10.1182/blood.V110.11.255.255

Published: 2007

Journal Articles

Targeting Wnt Signaling in Myeloma In Vivo ; Differential Effects on Tumor Burden and Myeloma Bone Disease.

Claire M. Edwards, PhD, James R. Edwards, PhD, Seint T. Lwin, Gregory R. Mundy, MD

Blood (2007) 110 (11): 812.

https://doi.org/10.1182/blood.V110.11.812.812

Published: 2007

Journal Articles

Genetic Polymorphisms Identify the Likelihood of Bone Disease in Myeloma: Correlations with Myeloma Cell DKK1 Expression and High Risk Gene Signatures.

Brian G.M. Durie, MD, Brian Van Ness, PhD, Christine Ramos, PhD, Owen Stephens, Majda Haznadar, Antje Hoering, PhD, Jeff Haessler, PhD, Michael S. Katz, BS, Gregory R. Mundy, MD, Robert A. Kyle, MD, Gareth J. Morgan, MD, PhD, John Crowley, PhD, Bart Barlogie, MD, John Shaughnessy, Jr., PhD

Blood (2007) 110 (11): 816.

https://doi.org/10.1182/blood.V110.11.816.816

Published: 2007

Journal Articles

Anti-α4 integrin antibody suppresses the development of multiple myeloma and associated osteoclastic osteolysis

Yoshihisa Mori, Nobuaki Shimizu, Mark Dallas, Maryla Niewolna, Beryl Story, Paul J. Williams, Gregory R. Mundy, Toshiyuki Yoneda

Blood (2004) 104 (7): 2149–2154.

https://doi.org/10.1182/blood-2004-01-0236

Published: 2004

Journal Articles

Dual effects of macrophage inflammatory protein-1α on osteolysis and tumor burden in the murine 5TGM1 model of myeloma bone disease

Babatunde O. Oyajobi, Giovanni Franchin, Paul J. Williams, Donna Pulkrabek, Anjana Gupta, Steve Munoz, Barry Grubbs, Ming Zhao, Di Chen, Barbara Sherry, Gregory R. Mundy

Blood (2003) 102 (1): 311–319.

https://doi.org/10.1182/blood-2002-12-3905

Published: 2003

Journal Articles

Cell–cell contact between marrow stromal cells and myeloma cells via VCAM-1 and α 4 β 1 -integrin enhances production of osteoclast-stimulating activity

Toshimi Michigami, Nobuaki Shimizu, Paul J. Williams, Maria Niewolna, Sarah L. Dallas, Gregory R. Mundy, Toshiyuki Yoneda

Blood (2000) 96 (5): 1953–1960.

https://doi.org/10.1182/blood.V96.5.1953

Published: 2000

Journal Articles

Ibandronate Reduces Osteolytic Lesions but not Tumor Burden in a Murine Model of Myeloma Bone Disease

Sarah L. Dallas, I. Ross Garrett, Babatunde O. Oyajobi, Mark R. Dallas, Brendan F. Boyce, Frieder Bauss, Jiri Radl, Gregory R. Mundy

Blood (1999) 93 (5): 1697–1706.

https://doi.org/10.1182/blood.V93.5.1697

Published: 1999

NARROW

Host-derived adiponectin is tumor-suppressive and a novel therapeutic target for multiple myeloma and the associated bone disease

Bone Spared Myeloma.

Osteoclasts in Myeloma Are Derived from Gr-1 + CD11b + Myeloid Immune Suppressor Cells of the Bone Marrow Niche in Vivo

Increasing Wnt signaling in the bone marrow microenvironment inhibits the development of myeloma bone disease and reduces tumor burden in bone in vivo

Protein Profiling in Myeloma In Vivo ; Effects of Bortezomib in a Mouse Model of Myeloma.

Targeting Wnt Signaling in Myeloma In Vivo ; Differential Effects on Tumor Burden and Myeloma Bone Disease.

Genetic Polymorphisms Identify the Likelihood of Bone Disease in Myeloma: Correlations with Myeloma Cell DKK1 Expression and High Risk Gene Signatures.

Anti-α4 integrin antibody suppresses the development of multiple myeloma and associated osteoclastic osteolysis

Dual effects of macrophage inflammatory protein-1α on osteolysis and tumor burden in the murine 5TGM1 model of myeloma bone disease

Cell–cell contact between marrow stromal cells and myeloma cells via VCAM-1 and α 4 β 1 -integrin enhances production of osteoclast-stimulating activity

Ibandronate Reduces Osteolytic Lesions but not Tumor Burden in a Murine Model of Myeloma Bone Disease

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only